The latest price target for Novo Nordisk (NYSE:NVO) was reported by Argus Research on December 8, 2025. The analyst firm set a price target for $0.00 expecting NVO to fall to within 12 months (a possible -100.00% downside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Novo Nordisk (NYSE:NVO) was provided by Argus Research, and Novo Nordisk downgraded their hold rating.

The last upgrade for Novo Nordisk AS happened on October 2, 2025 when HSBC raised their price target to $70. HSBC previously had a hold for Novo Nordisk AS.

The last downgrade for Novo Nordisk AS happened on December 8, 2025 when Argus Research changed their price target from N/A to N/A for Novo Nordisk AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on December 8, 2025 so you should expect the next rating to be made available sometime around December 8, 2026.

While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Novo Nordisk (NVO) is trading at is $49.76, which is out of the analyst’s predicted range.